Skip to content

Study · Non-randomized trial · n = 16 · 1995

15 results

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.

Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Dec 1995Cited by 108 (Europe PMC)

PMID8619364 (opens in a new tab)DOI10.1002/jbmr.5650101203 (opens in a new tab)PepBankPUB-08619364
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In elderly women, calcium excretion increased with all treatments, including both IGF-I doses.

    In plain wordsIn elderly women, calcium excretion increased with all treatments, including both IGF-I doses.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCalcium excretion
    Study

    n = 16

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 or 15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Twenty-four hour calcium excretion increased with all treatments.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In elderly women, hydroxyproline did not change with low-dose IGF-I.

    In plain wordsIn elderly women, hydroxyproline did not change with low-dose IGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeHydroxyproline
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    However, with low-dose IGF-I no change was observed in resorption markers while osteocalcin and CICP increased progressively (day 21, % increases = 88 +/- 51, 36 +/- 14).
    3 context sentences
    Summary · context
    Resorption markers included urine hydroxyproline (OHP), total pyridinolines (PYD), and N-telopeptide; formation markers include osteocalcin, skeletal alkaline phosphatase (sALP), and type I procollagen carboxy-terminal extension peptide (CICP).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In elderly women, total pyridinolines did not change with low-dose IGF-I.

    In plain wordsIn elderly women, total pyridinolines did not change with low-dose IGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeTotal pyridinolines
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    However, with low-dose IGF-I no change was observed in resorption markers while osteocalcin and CICP increased progressively (day 21, % increases = 88 +/- 51, 36 +/- 14).
    3 context sentences
    Summary · context
    Resorption markers included urine hydroxyproline (OHP), total pyridinolines (PYD), and N-telopeptide; formation markers include osteocalcin, skeletal alkaline phosphatase (sALP), and type I procollagen carboxy-terminal extension peptide (CICP).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In elderly women, N-telopeptide did not change with low-dose IGF-I.

    In plain wordsIn elderly women, N-telopeptide did not change with low-dose IGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeN-telopeptide
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    However, with low-dose IGF-I no change was observed in resorption markers while osteocalcin and CICP increased progressively (day 21, % increases = 88 +/- 51, 36 +/- 14).
    3 context sentences
    Summary · context
    Resorption markers included urine hydroxyproline (OHP), total pyridinolines (PYD), and N-telopeptide; formation markers include osteocalcin, skeletal alkaline phosphatase (sALP), and type I procollagen carboxy-terminal extension peptide (CICP).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  5. 05HumanNon-randomized trialEfficacy outcome

    In elderly women, low-dose IGF-I progressively increased osteocalcin, with an 88% increase at day 21.

    In plain wordsIn elderly women, low-dose IGF-I increased osteocalcin, with an 88% increase at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in osteocalcin
    88%
    low-dose IGF-I, day 21
    Osteocalcin percent increase +/- uncertainty magnitude (type not stated)
    51%
    Low-dose IGF-I, day 21, 88 +/- 51

    Source sentences

    Summary
    However, with low-dose IGF-I no change was observed in resorption markers while osteocalcin and CICP increased progressively (day 21, % increases = 88 +/- 51, 36 +/- 14).
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  6. 06HumanNon-randomized trialEfficacy outcome

    In elderly women, low-dose IGF-I progressively increased CICP, with a 36% increase at day 21.

    In plain wordsIn elderly women, low-dose IGF-I increased CICP, with a 36% increase at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCICP
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in CICP
    36%
    low-dose IGF-I, day 21
    CICP percent increase +/- uncertainty magnitude (type not stated)
    14%
    Low-dose IGF-I, day 21, 36 +/- 14

    Source sentences

    Summary
    However, with low-dose IGF-I no change was observed in resorption markers while osteocalcin and CICP increased progressively (day 21, % increases = 88 +/- 51, 36 +/- 14).
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  7. 07HumanNon-randomized trialEfficacy outcome

    In elderly women, low-dose IGF-I significantly increased deoxyPYD only in the 0800-1200 h urine aliquot.

    In plain wordsIn elderly women, low-dose IGF-I increased deoxyPYD only in the 0800-1200 h urine sample.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseTimed deoxypyridinoline
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    When deoxyPYD was measured on these samples in the low-dose IGF-I group, a significant increase was observed only on the 0800-1200 h aliquot.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  8. 08HumanNon-randomized trialEfficacy outcome

    In elderly women, low-dose IGF-I decreased serum phosphorus by day 28.

    In plain wordsIn elderly women, low-dose IGF-I decreased serum phosphorus by day 28.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseSerum phosphorus
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Change in serum phosphorus
    −9.7%
    low-dose IGF-I, day 28; unit not written, sentence reports percent changes
    Reported +/- term for serum phosphorus change
    2.7 not stated
    low-dose IGF-I, day 28, accompanying -9.7; uncertainty type not stated
    P value for serum phosphorus decrease
    < 0.02 unitless
    low-dose IGF-I, day 28 versus baseline

    Source sentences

    Summary
    Serum phosphorus concentrations increased with GH (21.2 +/- 3.3%) and high-dose IGF-I (8.8 +/- 3.6%) by day 21 but actually decreased by day 28 (-9.7 +/- 2.7, p < 0.02) with low-dose IGF-I.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  9. 09HumanNon-randomized trialEfficacy outcome

    In elderly women, low-dose IGF-I did not decrease urinary phosphorus excretion.

    In plain wordsIn elderly women, low-dose IGF-I did not decrease urinary phosphorus excretion.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeUrinary phosphorus
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    15 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Urinary phosphorus excretion decreased with high-dose IGF-I only.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  10. 10HumanNon-randomized trialEfficacy outcome

    In elderly women, high-dose IGF-I increased total pyridinolines by 108% at day 21.

    In plain wordsIn elderly women, high-dose IGF-I increased total pyridinolines by 108% at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseTotal pyridinolines
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in total pyridinolines
    108%
    high-dose IGF-I, day 21

    Source sentences

    Summary
    For high-dose IGF-I, these increases were 108, 81, 77, and 111% (p < 0.02-0.002).
    3 context sentences
    Summary · context
    For GH, the increase in day 21 PYD, N-telopeptide, osteocalcin, and CICP was 143, 111, 53, and 81%, respectively (p < 0.96-0.02).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  11. 11HumanNon-randomized trialEfficacy outcome

    In elderly women, high-dose IGF-I increased N-telopeptide by 81% at day 21.

    In plain wordsIn elderly women, high-dose IGF-I increased N-telopeptide by 81% at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseN-telopeptide
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in N-telopeptide
    81%
    high-dose IGF-I, day 21

    Source sentences

    Summary
    For high-dose IGF-I, these increases were 108, 81, 77, and 111% (p < 0.02-0.002).
    3 context sentences
    Summary · context
    For GH, the increase in day 21 PYD, N-telopeptide, osteocalcin, and CICP was 143, 111, 53, and 81%, respectively (p < 0.96-0.02).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  12. 12HumanNon-randomized trialEfficacy outcome

    In elderly women, high-dose IGF-I increased osteocalcin by 77% at day 21.

    In plain wordsIn elderly women, high-dose IGF-I increased osteocalcin by 77% at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in osteocalcin
    77%
    high-dose IGF-I, day 21

    Source sentences

    Summary
    For high-dose IGF-I, these increases were 108, 81, 77, and 111% (p < 0.02-0.002).
    3 context sentences
    Summary · context
    For GH, the increase in day 21 PYD, N-telopeptide, osteocalcin, and CICP was 143, 111, 53, and 81%, respectively (p < 0.96-0.02).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  13. 13HumanNon-randomized trialEfficacy outcome

    In elderly women, high-dose IGF-I increased CICP by 111% at day 21.

    In plain wordsIn elderly women, high-dose IGF-I increased CICP by 111% at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCICP
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Increase in CICP
    111%
    high-dose IGF-I, day 21

    Source sentences

    Summary
    For high-dose IGF-I, these increases were 108, 81, 77, and 111% (p < 0.02-0.002).
    3 context sentences
    Summary · context
    For GH, the increase in day 21 PYD, N-telopeptide, osteocalcin, and CICP was 143, 111, 53, and 81%, respectively (p < 0.96-0.02).
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  14. 14HumanNon-randomized trialEfficacy outcome

    In elderly women, high-dose IGF-I increased serum phosphorus by 8.8% at day 21.

    In plain wordsIn elderly women, high-dose IGF-I increased serum phosphorus by 8.8% at day 21.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseSerum phosphorus
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Change in serum phosphorus
    8.8%
    high-dose IGF-I, day 21
    Serum phosphorus percent increase +/- uncertainty magnitude (type not stated)
    3.6%
    High-dose IGF-I, day 21, 8.8 +/- 3.6

    Source sentences

    Summary
    Serum phosphorus concentrations increased with GH (21.2 +/- 3.3%) and high-dose IGF-I (8.8 +/- 3.6%) by day 21 but actually decreased by day 28 (-9.7 +/- 2.7, p < 0.02) with low-dose IGF-I.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.
  15. 15HumanNon-randomized trialEfficacy outcome

    In elderly women, urinary phosphorus excretion decreased with high-dose IGF-I only.

    In plain wordsIn elderly women, urinary phosphorus excretion decreased with high-dose IGF-I only.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseUrinary phosphorus
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    60 micrograms/kg b.i.d. · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Urinary phosphorus excretion decreased with high-dose IGF-I only.
    2 context sentences
    Summary · context
    We evaluated the effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone (GH) on calciotropic hormones and bone turnover markers in 16 healthy elderly women 71.9 +/- 1.3 years of age (mean +/- SEM).
    Summary · context
    Specimens were collected for 6 consecutive days before initiating subcutaneous injections of GH (25 micrograms/kg/day, n = 5) and IGF-I at 60 micrograms/kg b.i.d. (high-dose, n = 5) or at 15 micrograms/kg b.i.d. (low-dose, n = 6) for 28 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.